Peptide services/genscript/LI

Ended Purchase Order Awarded Last action

Contract number
HHSN261201700504P
Awardee
Awarding agency
Obligated
$8,787

Award facts

Contract value 100% obligated
$8,786.64 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541711 Research and Development in Biotechnology
PSC
Q301 Reference Laboratory Testing
Set-aside
No set-aside
Competition
Not Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Piscataway, NJ 08854, USA

Award details come from SAM.gov/FPDS.

About this award

The National Cancer Institute awarded a purchase order to Genscript USA Inc. valued at $8,786.64 on August 15, 2017, for peptide services. Work is performed in Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of September 30, 2017. No set-aside category was applied.

Quick answers

Who was awarded contract HHSN261201700504P?

HHSN261201700504P was awarded to Genscript USA Inc. by National Cancer Institute (National Institutes of Health) on August 15, 2017.

How much is contract HHSN261201700504P worth?

The government has obligated $8,787 on HHSN261201700504P.

Was contract HHSN261201700504P competed?

The extent of competition for HHSN261201700504P was not competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award